Kenneth Mills is the founder of REGENXBIO. REGENXBIO has raised $110M in total funding. Latest round: Series D. Based in Rockville, MD.
Kenneth Mills is the Chairman of the Board at REGENXBIO, a leading biotechnology company in gene therapy. REGENXBIO focuses on developing treatments for central nervous system and retinal diseases, leveraging its proprietary NAV® Technology. The company raised over $110 million in total capital since its inception as of May 2015, with its latest funding being a $70.5 million Series D round.
Full founder directory · Investor directory · Company funding database · Fundraising library